6WG8
Fab portion of dupilumab with Crystal Kappa design
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | SYNCHROTRON |
Source details | APS BEAMLINE 31-ID |
Synchrotron site | APS |
Beamline | 31-ID |
Temperature [K] | 100 |
Detector technology | CCD |
Collection date | 2020-01-29 |
Detector | RAYONIX MX225-HS |
Wavelength(s) | 0.9793 |
Spacegroup name | P 21 21 21 |
Unit cell lengths | 59.356, 73.051, 105.119 |
Unit cell angles | 90.00, 90.00, 90.00 |
Refinement procedure
Resolution | 30.000 - 1.360 |
R-factor | 0.2098 |
Rwork | 0.209 |
R-free | 0.22310 |
Structure solution method | MOLECULAR REPLACEMENT |
Starting model (for MR) | self |
RMSD bond length | 0.006 |
RMSD bond angle | 1.177 |
Data reduction software | MOSFLM |
Data scaling software | SCALA |
Phasing software | PHASER |
Refinement software | REFMAC (5.8.0103) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 30.000 | 1.400 |
High resolution limit [Å] | 1.360 | 1.360 |
Rmerge | 0.680 | |
Number of reflections | 93311 | 6806 |
<I/σ(I)> | 21.5 | |
Completeness [%] | 99.9 | |
Redundancy | 6.5 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION, SITTING DROP | 294 | 100mM Hepes pH 7, 10% PEG MME 5K , 80mM tri-Sodium Citrate dihydrate pH 7 |